A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

November 18, 2024

Study Completion Date

November 18, 2024

Conditions
Alzheimer DiseaseHealthy
Interventions
DRUG

LY3372993

Administered IV or SC.

DRUG

Placebo

Administered IV or SC.

Trial Locations (13)

32127

Progressive Medical Research, Port Orange

32162

Charter Research, The Villages

Synexus Clinical Research US, Inc., The Villages

32720

Accel Research Sites- Clinical Research Unit, DeLand

33009

MD Clinical, Hallandale

33176

IMIC, Inc., Miami

75247

Covance Dallas, Dallas

90630

Altasciences Clinical Los Angeles, Inc, Cypress

90806

Collaborative Neuroscience Research, LLC, Long Beach

32806-1041

Ppd Development, Orlando

879-5503

Oita University Hospital, Yufu

113-8655

The University of Tokyo Hospital, Bunkyo-ku

162-0053

Clinical Research Hospital Tokyo, Shinjuku-ku

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04451408 - A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants | Biotech Hunter | Biotech Hunter